🇺🇸 FDA
Patent

US 11179328

Compositions and methods for the treatment of presbyopia

granted A61KA61K31/439A61K31/4409

Quick answer

US patent 11179328 (Compositions and methods for the treatment of presbyopia) held by Lenz Therapeutics, Inc. expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Lenz Therapeutics, Inc.
Grant date
Tue Nov 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/439, A61K31/4409, A61K45/06, A61K47/02